Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ATHENA’s First Launch in Russia with Levocetirizine ODT
Details : Levocetirizine ODT is second-generation piperazine derivative with potent H1-selective antihistaminic activity,n Improved oral bioavailability and onset of action vs. conventional oral slide form by avoiding hepatic first-pass effect.
Brand Name : Levocetirizine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2020
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?